atop
dermat
ad
refractori
recurr
inflammatori
skin
diseas
hered
environment
agent
immun
skin
barrier
function
particip
pathogenesi
ad
ad
symptom
trigger
variou
nonspecif
specif
allerg
reaction
cytokin
pattern
ad
especi
acut
phase
skin
lesion
cytokin
domin
barrier
disrupt
skin
ad
easili
permit
percutan
entri
environment
allergen
strongli
promot
immunolog
respons
cell
well
regulatori
cell
treg
subset
play
key
role
develop
ad
patient
ad
significantli
increas
number
peripher
blood
treg
compar
healthi
control
correl
diseas
activ
ad
suggest
involv
self
regul
system
immun
respons
ad
repeat
elicit
hapten
oxazolon
ox
ear
balbc
mice
develop
immedi
type
respons
late
phase
reaction
follow
delay
type
hypersensit
respons
accompani
balanc
shift
cytokin
lesion
skin
type
util
mous
ad
major
secretori
protein
well
conserv
mycobacterium
speci
studi
tuberculosi
vaccin
reveal
strong
activ
prime
cell
effector
cell
appropri
condit
induct
strong
immun
respons
mice
well
human
recent
report
plasmid
dna
vaccin
encod
deriv
kansasii
inhibit
immediatetyp
hypersensit
respons
treg
induct
skin
combin
vaccin
heatkil
bcg
follow
also
suppress
skin
eczemat
reaction
ad
model
mice
induc
treg
human
parainfluenza
type
viru
one
human
respiratori
pathogen
member
genu
rubulaviru
famili
paramyxovirida
order
mononegaviral
possess
nonseg
negativestrand
rna
genom
nucleotid
genom
encod
mrna
leader
sequenc
end
noncod
trailer
sequenc
gene
order
leader
npvpmfhnl
trailer
code
protein
nucleocapsid
np
v
v
phospho
p
matrix
fusion
f
haemagglutininneuraminidas
hn
polymeras
protein
l
genom
rna
viru
viral
rna
vrna
encapsid
np
protein
nucleocapsid
associ
p
l
protein
form
ribonucleoprotein
complex
paramyxoviru
particl
vrna
enclos
viral
envelop
compos
cellular
lipid
bilay
two
envelop
glycoprotein
hn
f
integr
transmembran
protein
mediat
viru
attach
cell
fusion
respect
protein
underli
lipid
bilay
ensur
structur
integr
viral
particl
essenti
interact
viral
envelop
rnp
complex
associ
lead
bud
releas
viral
particl
cell
surfac
recent
technolog
advanc
revers
genet
hpiv
offer
sever
advantag
vaccin
vector
hpiv
effici
infect
respiratori
tract
spread
far
beyond
import
safeti
factor
hpivbas
vector
proven
effect
induc
local
system
immun
number
foreign
antigen
hpiv
infect
variou
cell
type
caus
littl
cytopath
effect
moreov
replic
exclus
cytoplasm
infect
cell
dna
phase
life
cycl
thu
avoid
possibl
integr
foreign
gene
host
dna
genom
present
studi
util
newli
engin
replicationdefici
vector
lack
gene
essenti
gene
viru
particl
format
insert
two
stop
codon
alter
might
support
much
safer
applic
anim
origin
prolifer
viru
vector
first
investig
effici
vaccin
vector
express
enhanc
green
fluoresc
protein
egfp
gene
infect
express
vitro
vivo
evalu
effect
vaccin
pathway
subcutan
intranas
administr
express
gene
mice
ad
model
induc
repeat
hapten
challeng
balbc
old
male
mice
purchas
japan
slc
co
shizuoka
japan
use
anim
care
perform
accord
ethic
guidelin
approv
institut
board
committe
anim
care
use
mie
univers
construct
accord
method
report
previous
except
method
suppli
rna
polymeras
np
p
l
brief
gener
replicationdefici
vector
two
nucleotid
chang
atg
tag
posit
aag
tag
introduc
frame
plasmid
fulllength
cdna
copi
antigenom
fig
consequ
n
length
cdna
egfp
follow
transcript
end
sequenc
np
gene
intergen
sequenc
ig
transcript
start
signal
vp
gene
synthes
pcr
use
appropri
primer
insert
site
plasmid
dna
encod
replicationdefici
genom
describ
virus
recov
cotransfect
antigenom
plasmid
plasmid
express
np
p
l
clone
mammalian
gene
express
vector
pcagg
cell
express
rna
polymeras
cell
harvest
cocultur
fresh
vero
cell
everi
hr
approxim
cell
show
syncytia
format
cocultur
cell
state
maintain
cocultur
furthermor
viru
propag
cell
transfect
plasmid
express
cocultur
abovement
cell
supernat
centrifug
g
h
viru
pellet
suspend
optimem
invitrogen
carisbad
ca
usa
viru
titer
determin
cpe
method
use
vero
cell
express
tissu
cultur
infecti
dose
hacat
cell
cell
line
servic
eppelheim
germani
cultur
dulbecco
mem
supplement
vv
fb
mm
lglutamin
uml
penicillin
mgml
streptomycin
hacat
cell
seed
one
day
transduct
cellsml
mlwell
cultur
plate
costar
ny
usa
cell
incub
hour
atmospher
next
day
media
remov
ml
virus
ad
cell
adjust
two
hour
infect
media
remov
fresh
cultur
media
supplement
cell
day
cultur
well
observ
fluoresc
microscopi
next
step
concentr
administ
caviti
nose
mice
four
day
infect
respiratori
tract
lung
sampl
embed
tissuetek
oct
compound
mile
elkhart
usa
frozen
liquid
nitrogen
cut
section
section
examin
record
fluoresc
microscopi
repeat
hapten
sensit
challeng
system
introduc
experi
ox
sigma
st
loui
mo
dissolv
acetoneol
oil
shown
fig
mice
initi
sensit
past
ox
solut
right
ear
day
prior
first
challeng
day
ox
solut
repeatedli
appli
right
ear
time
per
week
day
day
repeat
applic
ox
caus
delay
type
hypersensit
follow
immediatetyp
late
phase
reaction
vaccin
mice
infect
intranas
gener
anesthesia
viru
inoculum
phosphatebuff
salin
pb
day
day
mice
vaccin
pb
control
vector
intranas
subcutan
pinna
skin
fig
c
ear
swell
measur
thick
gaug
calip
hour
last
ox
challeng
day
blood
pinna
skin
also
sampl
ear
skin
sampl
six
hour
last
ox
challeng
day
sampl
fix
neutral
buffer
formaldehyd
embed
paraffin
histolog
section
mm
thick
stain
hematoxylin
eosin
h
e
mrna
extract
mous
ear
use
isogen
nippon
gene
tokyo
japan
accord
manufactur
instruct
one
ml
homogen
mix
chloroform
centrifug
aqueou
phase
separ
mix
ml
nacalai
tesqu
kyoto
japan
precipit
rna
centrifug
precipit
wash
ethanol
nacalai
tesqu
rna
suspend
rnasefre
water
concentr
rna
measur
nm
absorb
qualiti
confirm
electrophoresi
cdna
synthes
mrna
use
archiv
kit
appli
biosystem
foster
citi
ca
usa
accord
manufactur
protocol
real
time
quantit
revers
transcriptionpolymeras
chain
reaction
rtpcr
perform
measur
transcript
activ
skin
lesion
reaction
mixtur
contain
cdna
nm
primer
nm
taqman
probe
mix
taqman
master
mix
ab
quantit
rtpcr
cytokin
transcript
perform
use
prequalifi
primer
probe
gapdh
ab
method
use
standard
transcript
gapdh
ratio
control
mice
calcul
ear
skin
sampl
day
snapfrozen
frozen
section
prepar
thick
subject
block
procedur
normal
goat
serum
vector
laboratori
burlingam
ca
section
incub
fitcconjug
rat
antimous
antibodi
beckman
coulter
pe
conjug
antimous
antibodi
biolegend
examin
fluoview
laser
scan
confoc
microscopi
olympu
tokyo
japan
skin
infiltr
cell
cell
count
field
number
randomli
chosen
field
five
sampl
evalu
serum
ige
level
determin
sandwich
enzymelink
immunosorb
assay
yamasa
tokyo
japan
accord
manufactur
instruct
optic
densiti
well
determin
use
micropl
reader
multiscan
jx
thermo
electron
yokohama
japan
statist
analysi
perform
use
mannwhitney
utest
p
consid
signific
investig
express
level
insert
gene
vitro
hacat
cell
infect
moi
examin
directli
use
fluoresc
microscopi
egfp
highli
express
hacat
cell
remark
fluoresc
extend
nearli
cell
spite
low
moi
fig
evalu
gene
express
vivo
mice
intranas
inocul
intens
egfp
express
reveal
lung
epithelium
mice
fig
evalu
clinic
relev
therapi
mice
treat
follow
strategi
shown
fig
ear
lobe
vector
alon
pbstreat
mice
develop
sever
edemat
erythema
exud
eros
hour
ox
challeng
day
howev
reduc
dermat
intranas
subcutan
applic
group
fig
ear
swell
dramat
suppress
mice
compar
pb
treat
mice
fig
pb
mice
show
mark
inflammatori
reaction
acanthosi
ulcer
epidermi
mark
edema
cellular
infiltr
includ
mononuclear
cell
neutrophil
dermi
intranas
subcutan
applic
success
reduc
inflammatori
cell
infiltr
epiderm
thick
fig
high
level
ige
detect
sera
pb
mice
hand
ige
level
sera
mice
two
way
suppress
significantli
fig
express
mrna
significantli
decreas
ear
skin
intranas
treatment
group
compar
pb
treat
mice
fig
clear
contrast
mrna
express
significantli
increas
intranas
treat
group
fig
expect
level
significantli
increas
intranas
treat
group
fig
surprisingli
express
remark
elev
intranas
group
fig
mrna
express
significantli
decreas
intranas
subcutan
treat
group
compar
pb
vector
treat
group
fig
f
express
mrna
also
significantli
elev
intranas
subcutan
treat
group
fig
obviou
suppress
mrna
express
detect
group
fig
shown
fig
cell
display
green
fluoresc
cell
red
merg
yellow
color
mean
cell
skin
infiltr
cell
significantli
decreas
ag
nasal
group
ag
ear
group
compar
pbstreat
group
although
reach
signific
cell
number
less
ag
nasal
group
compar
ag
ear
group
fig
cell
significantli
increas
ag
nasal
ag
ear
group
fig
immun
system
fine
control
balanc
four
main
subset
treg
cell
ad
especi
acut
phase
diseas
cell
dominantli
involv
pathogenesi
fact
pbmc
patient
ad
increas
product
limit
capac
product
repeat
elicit
ox
mice
ear
shift
cutan
cytokin
milieu
repres
characterist
immunolog
featur
ad
immunotherapi
ad
differ
option
correct
imbal
shift
cytokin
profil
present
studi
investig
effect
vaccin
use
replicationdefici
vector
express
gene
mous
ad
model
bcg
known
strong
respons
modifi
howev
risk
granuloma
format
avoid
granuloma
format
nonwax
protein
antigen
requir
conserv
protein
mycobacteri
speci
elicit
strong
immun
respons
therefor
use
immunemodul
control
acut
ad
lesion
asthma
dna
vaccin
suppress
airway
inflamm
murin
model
asthma
furthermor
resent
studi
suggest
vaccin
promot
immun
respons
well
treg
respons
administr
show
therapeut
effect
cytokin
mediat
acut
phase
ad
model
induc
regulatori
cell
select
vector
applic
pathway
import
success
dna
vaccin
therapi
select
potenti
vector
vaccin
hpiv
human
respiratori
pathogen
distinct
clinic
featur
infect
hpiv
croup
ie
laryngotracheobronch
swell
around
vocal
chord
part
upper
middl
airway
among
hpiv
major
caus
croup
children
wherea
rare
identifi
clinic
pathogen
therefor
suspect
less
virul
cytotox
viru
enter
cell
cell
fusion
plasma
membran
replic
exclus
cytoplasm
bud
plasma
membran
therefor
risk
integr
host
genom
like
retroviru
addit
sinc
nonseg
negativestrand
rna
genom
antigen
shift
among
rna
segment
like
influenza
virus
use
technolog
advanc
revers
genet
constitut
replicationdefici
vector
addit
advantag
highli
safe
viru
vector
confirm
target
effect
infect
vector
inocul
hacat
cell
hacat
cell
success
express
egfp
day
postinfect
pi
also
balbc
mice
intranas
singleadministr
show
intens
egfp
express
airway
epitheli
cell
result
strongli
support
activ
longterm
highlevel
express
exogen
gene
effici
vivo
present
studi
ad
symptom
includ
ear
swell
late
phase
reaction
significantli
suppress
treat
group
intranas
subcutan
administr
inflammatori
cell
infiltr
includ
mast
cell
eosinophil
lesion
skin
also
suppress
cytokin
profil
mrna
express
ear
skin
significantli
increas
interestingli
mrna
significantli
reduc
intranas
treat
group
suppress
induct
intranas
applic
show
stronger
effect
compar
subcutan
applic
viru
infecti
respiratori
tract
mucosa
therefor
effect
captur
respiratori
epithelium
compar
skin
resid
cell
reason
addit
skin
deriv
antiinfecti
molecul
horni
layer
proteas
epitheli
skin
barrier
might
decreas
effici
treg
induct
effect
therapi
import
present
studi
unveil
augment
express
intranas
describ
critic
regulatori
cytokin
produc
treg
fact
current
experi
number
skin
infiltr
cell
decreas
nasal
applic
ear
skin
applic
group
accompani
increas
treg
popul
heatkil
mycobacterium
vacca
vacca
give
rise
allergen
specif
regulatori
cell
produc
confer
protect
airway
inflamm
recent
prove
suppress
function
signal
control
cellmedi
inflamm
addit
crucial
effect
induct
treg
without
obviou
effect
clinic
manifest
balanc
conclus
respiratori
tract
epithelium
captur
effect
without
remark
cytotox
effect
treatment
especi
transnas
mucosa
approach
amelior
oxinduc
ad
model
alter
cytokin
balanc
induct
regulatori
cytokin
induct
thu
nasal
vaccin
novel
less
invas
use
therapeut
approach
ad
relat
allerg
disord
